Bacil Pharma Approves ₹50 Cr Rights Issue, Capital Increase

Bacil Pharma Ltd's Board of Directors met on July 9, 2026, approving a Rights Issue of equity shares to raise up to ₹50 crore. The board also approved an increase in authorized share capital by ₹45 crore to ₹65 crore, subject to shareholder approval. Intermediaries for the Rights Issue were appointed, including Purva Sharegistry as Registrar and Axis Bank as Banker. The board accepted the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya. A Rights Issue Committee was formed, and Ms. Chaitali Kalpataru Shah (Executive Director & CFO) and the Company Secretary were authorized to execute necessary documents for the Rights Issue. The trading window remains closed until 48 hours after the meeting outcome.